Category: Replacement Heart ValvesSyndicate content

Heart Valves

On-X Life Technologies launches mitral valve chord repair system

May 22, 2015 by Fink Densford

On-X Life Technologies says it's launching a mitral valve chordal repair system, dubbed Chord-X.

On-X Life Technologies launches mitral valve chord repair system

On-X Life Technologies said it's launching Chord-X, a new mitral valve chordal repair system using the company's proprietary sutures.

EuroPCR 2015: Edwards pauses Fortis TMVI, TAVI gains across the board

May 22, 2015 by Fink Densford

Replacement heart valves once again take center stage at the annual EuroPCR conference in Paris this week, as Edwards Lifesciences pauses its Fortis trial and positive new data comes in on the next generation of aortic implants.

EuroPCR 2015: Edwards pauses Fortis TMVI, TAVI gains across the board

TAVI: Study shows 80% survival at 2 years for Direct Flow device

May 19, 2015 by Fink Densford

Direct Flow Medical says 2-year data from its Discover CE Mark trial showed an 80% survival rate at 2 years for its transcatheter aortic valve implant.

TAVI: Study shows 80% survival at 2 years for Direct Flow device

Direct Flow Medical today said data from a clinical trial of its replacement heart valve showed an 80% survival rate after 2 years.

Blood clots prompt trial pause for Edwards' Fortis mitral valve

May 19, 2015 by Brad Perriello

Edwards Lifesciences halts enrollment in a clinical trial of its Fortis mitral valve implant after some patients developed blood clots in the devices.

Blood clots force trial pause for Edwards' Fortis mitral valve

Trial delays, Q1 profit slide pushes Neovasc shares down

May 15, 2015 by Fink Densford

Delays in Neovasc’s early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits push its stock price down.

Trial delays, Q1 profit slide hit Neovasc shares

Delays in Neovasc's (NSDQ:NVCN) early feasibility trial for its Tiara transcatheter mitral valve implant and declining 1st-quarter profits combined to push its stock price down this week.

HRS 2015: Study shows Abbott's MitraClip halves arrhythmias

May 14, 2015 by Fink Densford

Abbot’s MitraClip cut ventricular tachyarrhythmias by 50% in patients with mitral regurgitation and a rhythm management device.

HRS 2015: MitraClip study shows 50% reduction in tachyarrhythmias for patients with coexisting cardiac devices

Biotronik looks to get into the TAVI game

May 12, 2015 by Brad Perriello

Biotronik touts 1st-in-human data for its entry into the transcatheter aortic valve implant market, saying the device passed its 30-day safety endpoint.

Biotronik looks to get into the TAVI game

Biotronik today said its entry into a hot replacement heart valve market passed the safety endpoint of a 1st-in-human trial.

The German medical device giant said the Biovalve trial of its transcatheter aortic valve implant established the device's early safety at 30 days.